医疗支付解决方案公司Claritev Corporation（股票代码：CTEV）今日盘前大跌9.59%，引发市场关注。导致股价下跌的主要原因是公司第一大股东私募股权投资公司Hellman & Friedman（H&F）宣布减持150万股股票。
根据公司公告，此次减持的发行价为51.50美元，较股票最后收盘价折价12.1%。减持完成后，H&F的持股量将降至约390万股，占Claritev已发行股票的23.5%。此次股票发行由巴克莱、古根海姆和富国银行牵头，花旗集团和Piper Sandler担任账簿管理人。
值得注意的是，尽管此次减持对股价造成了短期压力，但Claritev的股价自年初以来已上涨约四倍。同时，根据LSEG的数据，目前所有3位覆盖Claritev的分析师都对公司持看涨态度，其目标价分别为80美元、90美元和95美元。这表明尽管发生大股东减持，分析师仍对公司的长期发展前景保持乐观。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.